ERBB2 and breast carcinoma: Razazan et al. [71] also reported the development of a liposome vaccine encapsulating Gp2 (a MHC class I peptide derived from HER2/neu) and monophosphoryl lipid A. After vaccination, they observed enhanced antitumor immunity, decreased tumor size, and longer survival time in a breast cancer mouse model overexpressing HER2/neu.